Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
Author:
Funder
Y-mAbs Therapeutics
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pediatrics, Perinatology and Child Health
Link
https://link.springer.com/content/pdf/10.1007/s40272-022-00544-9.pdf
Reference27 articles.
1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. https://doi.org/10.1016/S0140-6736(07)60983-0.
2. Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369–86. https://doi.org/10.1080/14737140.2017.1285230.
3. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34. https://doi.org/10.1056/NEJMoa0911123.
4. Mora J, Castañeda A, Gorostegui M, Santa-María V, Garraus M, Muñoz JP, et al. Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. Pediatr Blood Cancer. 2021;68: e29121. https://doi.org/10.1002/pbc.29121.
5. Cheung NK, Lazarus H, Miraldi FD, Abramowsky CR, Kallick S, Saarinen UM, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5(9):1430–40.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions;Frontiers in Cell and Developmental Biology;2024-03-27
2. GD2-targeting therapy: a comparative analysis of approaches and promising directions;Frontiers in Immunology;2024-03-15
3. Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's Hospital;Cancer Medicine;2024-02
4. Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System;Pediatric Drugs;2023-12-28
5. Correction to: Multidisciplinary Clinical Care in the Management of Patients Receiving Anti‑GD2 Immunotherapy for High‑Risk Neuroblastoma;Pediatric Drugs;2023-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3